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Abstract In this review, the importance of growth hor-
mone (GH) for the maintenance of normal cardiac function
in adult life is discussed. Physiological effects of GH and
underlying mechanisms for interactions between GH and
insulin-like growth factor I (IGF-I) and the cardiovascular
system are covered as well as the cardiac dysfunction
caused both by GH excess (acromegaly) and by GH defi-
ciency in adult hypopituitary patients. In both acromegaly
and adult GH deficiency, there is also increased cardio-
vascular morbidity and mortality possibly linked to aber-
rations in GH status. Finally, the status of the GH/IGF-I
system in relation to heart failure and the potential of GH
as a therapeutic tool in the treatment of heart failure are
reviewed in this article.
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Introduction
Besides well-recognized effects such as promoting longi-
tudinal bone growth in childhood and exerting a number of
metabolic effects, growth hormone (GH) has an important
role for the development of a normal heart [1]. GH also has
a major impact on maintaining the structure and function of
the normal adult heart [1, 2]. Apart from stimulating cardiac
growth and possibly also contractility, GH/IGF-I interacts
with the vascular system and has a role in the regulation of
vascular tone and thereby peripheral resistance. Also central
effects including modulation of sympathetic outflow con-
tribute to regulation of peripheral resistance [3].
The myocardium and vessels express IGF-I [4–6] and
functional receptors for both GH [7–9] and IGF-I [10, 11],
and IGF-I production is up-regulated in response to GH [5].
Thus, there are possibilities of direct actions of GH as well
as endocrine or autocrine/paracrine effects of IGF-I on the
cardiovascular system. However, although interaction of
the GH/IGF-I axis and the cardiovascular system has been
extensively studied, the relative importance of direct
effects of GH and local and endocrine IGF-I remains
unclear.
Vascular effects of GH and IGF-I
Regulation of peripheral resistance
Both GH and IGF-I have been suggested to have a regu-
latory role for peripheral resistance, although it is often
difficult to differentiate between direct effects of GH and
effects mediated by IGF-I. Evidence to suggest rapid
vasoactive effects of IGF-I includes the finding that intra-
venous administration of IGF-I decreases mean arterial
blood pressure within a few minutes in normal rats [12,
13]. In a human study, stroke volume and cardiac output
were increased, but blood pressure unchanged a few hours
after a single injection of IGF-I [14]. Moreover, in patients
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with chronic heart failure (CHF), IGF-I infusion increased
cardiac output and decreased peripheral resistance within a
time span of 2 h [15]. A similar effect of GH was seen after
24 h when serum IGF-I was concomitantly increased [16].
These data suggest that IGF-I has potent, acute functional
effects on the cardiovascular system. In a more recent
study, it was shown in healthy subjects that GH directly
increased forearm blood flow paralleled by a decrease in
peripheral resistance [17]. Moreover, these changes were
suggested to be mediated by stimulation of endothelial
function through the NO system. However, the effect was
not seen until 4 h after GH infusion, and it is possible that
GH actions were mediated by local production of IGF-I in
the periphery.
Despite accumulating evidence supporting the vasodi-
lating effects of IGF-I, there have only been a few studies
addressing the role of IGF-I in more long-term, physio-
logical regulation of peripheral resistance. Lembo et al.
[18] showed that mice with a mutant IGF-I allele and 30 %
of wild-type IGF-I levels present in all tissues, and serum
have elevated blood pressure. In analogy, transgenic mice
with a liver-specific knock-out of IGF-I and an 80 %
decrease of circulating IGF-I also display a significant
elevation of blood pressure, indicating that a decrease in
endocrine-acting IGF-I results in an elevation of blood
pressure [19].
Several studies suggest that the vascular actions of IGF-I
may be mediated through release of NO and/or other
vasodilators from the endothelium. IGF-I stimulates NO
release from cultured endothelial cells [20], vascular
smooth muscle cells [21] as well as aortic preparations [13].
Pre-treatment with the NO-synthase inhibitor L-NAME is
capable of abolishing the vasodilatory effect of IGF-I in
large arteries [12, 22–24]. There are also reports of eico-
sanoids as mediators of the vasodilating effects of IGF-I and
that indomethacin may prevent vasodilatation by IGF-I [22,
24, 25]. Moreover, IGF-I may cause vasorelaxation through
non-endothelium-dependent actions [26], possibly by
increasing the activity of the Na?, K?-ATPase in vascular
smooth muscle cells [27]. Another possible mechanism for
the GH/IGF-I influence on vascular tone involves the reg-
ulation of gene expression of the vascular smooth muscle
KATP channel [28]. This ATP sensitive potassium channel
consists of two subunits, the inwardly rectifying potassium
channel Kir6.1 and the sulfonylurea receptor 2B (SUR2B)
[29] where Kir6.1 has been proposed to be critical for reg-
ulation of vascular tone [30]. Moreover, the smooth muscle
KATP channel is also the target for the anti-hypertensive
potassium channel opening drugs [29]. GH treatment of
hypophysectomized (hx) rats resulted in increased mRNA
levels of both Kir6.1 and SUR2B, and this was correlated to
a lowering of systolic blood pressure [28].
Central effects
It has also been suggested that some vasoactive effects of
GH may have central origin. In a comparison between
GH-deficient (GHD) patients without GH substitution and
healthy controls matched for BMI, it was shown that
GHD patients had markedly increased muscle sympathetic
nerve activity [3]. Moreover, 1 year of substitution ther-
apy with GH had a modest but significant effect on
decreasing sympathetic nerve activity to the muscle vas-
cular bed [31]. This could suggest that GH may regulate
the central sympathetic outflow affecting peripheral
resistance.
Vascular consequences of GHD
Conflicting results regarding blood pressure and peripheral
resistance have been reported in the literature, although it
appears that at least in certain patients, GH treatment can
lower peripheral resistance. In GH-deficient adults without
GH replacement therapy, an increased prevalence of
hypertension was reported in a large study that mainly
consisted of adult-onset GH-deficient patients [32]. How-
ever, unchanged blood pressure has also been reported [33]
and in studies mainly consisting of young GH-deficient
adults, even reduced blood pressure has been reported [34–
36]. In another study, GH replacement therapy did not
affect systolic blood pressure, whereas diastolic blood
pressure was decreased due to reduced peripheral vascular
resistance [37]. Also in men with the metabolic syndrome
but without severe GH deficiency, a lowering of diastolic
blood pressure was observed after GH treatment for
9-months [38]. A stimulatory effect of GH on nitric oxide
production [39] could possibly explain the reduced
peripheral vascular resistance and the reduction in diastolic
blood pressure in response to GH supplementation that
have been observed in some trials. However, there are also
studies showing unchanged [40] or even increased [41]
blood pressure during GH replacement. Taken together, it
can be speculated that GH replacement reduces blood
pressure only in subgroups of GH-deficient adults, possibly
in patients with high base-line diastolic blood pressure
[42], such as GH-deficient patients with previous Cushing´s
disease or elderly GH-deficient adults.
Atherosclerosis has also been observed in hypopituitary
adults without GH replacement therapy. In a study by
Markussis et al. [33], increased carotid artery wall thick-
ness was observed in GH-deficient adults. The results of
several later studies suggest that GH replacement may
reverse early atherosclerotic changes in the carotid arteries
in GH-deficient adults [43, 44].
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Vasculature in GH excess
It would appear that more short-term exposure to high
levels of GH leads to a decrease of peripheral resistance.
Some pioneering experimental studies focusing on the
hemodynamic effects of chronic GH hypersecretion
employed a rat model with an implantable GH-secreting
tumor was used as an experimental model [45]. These rats
displayed cardiomegaly and increased cardiac contractility
and output, while peripheral resistance was decreased [45].
In human acromegalics, three stages of cardiovascular
disease have been identified—an early, intermediate and
late stage of the disease [1]. Interestingly, although rarely
diagnosed in the early stage, patients with only a relatively
short duration of acromegaly display a ‘‘hyperkinetic’’
cardiovascular system with increased cardiac output and
decreased total peripheral resistance [1]. However, if the
disease is not treated, it progresses into more advanced
stages with hypertension as a common finding. Hyperten-
sion has been reported in the bGH mouse model [46] and in
humans, studies suggest a prevalence of hypertension of
20–50 % in acromegalic patients [47]. The mechanisms for
the increased prevalence of hypertension have been sug-
gested to include an expansion of plasma volume, stimu-
lation of smooth muscle cell growth leading to increased
vascular resistance, and increased insulin resistance as a
potential facilitator of increased blood pressure (for review
see: [48]).
The prevalence of atherosclerosis in acromegalic
patients is controversial. However, recent studies suggest
that acromegalic patients do not have increased prevalence
of coronary artery disease [49, 50], carotid atherosclerosis,
or carotid internal media thickness compared to normal
subjects [49, 51]. In a recent European study on 200
acromegalic patients matched with a control group, it was
reported that patients with active acromegaly had signifi-
cantly lower levels of high-sensitive C-reactive protein (hs-
CRP) both compared with patients with controlled acro-
megaly and with a matched reference population [52].
Possibly, a lower hs-CRP may be linked to lower than
expected prevalence of atherosclerosis in patients with
active acromegaly, despite the presence of other risk fac-
tors such as insulin resistance and hypertension.
Effects of GH and IGF-I on cardiac structure
Growth and development
It is generally difficult to demonstrate in vitro effects of
GH, and consequently, many studies have failed to show
direct, IGF-I-independent hypertrophic effects of GH on
cardiomyocytes [53, 54]. However, it has been suggested
that GH may cause alterations in cardiomyocyte metabo-
lism and stimulate cardiac growth independently of IGF-I
[55, 56]. When performing in vitro studies, it is easier to
see effects of IGF-I compared to GH, and many studies
have shown that IGF-I increases protein synthesis [53, 57]
and the size of cardiomyocytes [54] in vitro.
Several genes have been identified as targets of GH and
IGF-I, and it has previously been shown that IGF-I stim-
ulates the expression of muscle-specific genes in rat
cardiomyocytes [54]. In hx rats, GH and IGF-I treatment
stimulated similar cardiac gene expression (skeletal
a-actin, atrial natriuretic factor) but neither IGF-I nor GH
caused a shift of myosin heavy chain isoforms [58].
Interestingly, it has been shown that expression of activated
calcineurin mimics the hypertrophic effects of IGF-I in
skeletal muscle [59].
Cardiac hypertrophy requires concomitant remodeling
of the heart, and attention has been focused on the role of
the extracellular matrix in the remodeling process [60]. It
has been shown that IGF-I promotes collagen synthesis by
fibroblasts [61] and that GH increases the collagen depo-
sition rate in the heart [62], while in GH-induced hyper-
trophy, the volume fraction of collagen is normal [63, 64].
Thus, available data are in line with an increased synthesis
as well as breakdown of extracellular matrix with a finally
unchanged cardiac collagen concentration by GH.
Besides obvious growth promoting effects on cardio-
myocytes, GH and IGF-I may also modulate the structure
of the myocardium by preventing cardiomyocyte loss
through apoptosis. Ongoing apoptosis has been demon-
strated also in the normal heart [65], and there is substantial
evidence that IGF-I acts as an inhibitor of apoptosis. In line
with this, it has been proposed that an anti-apoptotic effect
GH/IGF-I may serve to protect the myocardium in condi-
tions with ischemic injury [66, 67]. However, although an
increased number of nuclei in the heart of GH-treated adult
rats have been reported [64], there is still no evidence that
GH or IGF-I can affect cardiomyocyte number in the
normal heart unless overexpressed from the embryonic cell
stage [68].
Cardiac structure in GHD
A number of studies have addressed cardiac structure in
patients lacking GH. It has been reported that GH-deficient
adults without GH replacement therapy have reduced left
ventricular mass and cardiac output [34] and decreased
exercise capacity [1]. The results of some studies suggest
that the cardiac dysfunction may be more severe in GH-
deficient patients with childhood-onset disease than in
patients with adult-onset disease due to the lack of GH/
IGF-I during growth and development of the heart [34]. In
a study by Longobardi et al. [69], however, patients with
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childhood- and adult-onset disease younger than 40 years
of age were studied using equilibrium radionucleotide
angiography. In this study, left ventricular ejection fraction
was decreased by 17 % at rest and 29 % at peak exercise as
compared with age- and sex-matched controls without any
difference between childhood- and adult-onset disease
[69].
Short-term and placebo-controlled studies have shown
that GH replacement therapy in adult GH-deficient patients
has an anabolic effect on cardiac structure [35, 37, 70],
resulting in an improvement in both diastolic [71], and
systolic [35, 37, 70, 72] function. A few open label studies
have determined the long-term effects of GH replacement
therapy on cardiac function. Thirty-eight months of GH
replacement therapy normalized cardiac structure, whereas
heart rate and cardiac index increased to supranormal
levels [73]. In another study, including 38 young men with
childhood-onset GH deficiency, GH replacement therapy
for 55 months (range 39–69) increased stroke volume and
maximal exercise capacity without any long-term increase
in left ventricular mass [41].
In 7 adults with adult-onset GH deficiency, 42 months
of open GH treatment increased the left ventricular mass
and decreased the atrial emptying index, which reflects
diastolic function, as compared with healthy matched
controls [74]. The results of this last study might suggest,
although a higher dose of GH was given than that used
today, that increased age might increase the susceptibility
to develop inappropriate increment in left ventricular mass
during long-term GH replacement therapy. Therefore,
studies so far suggest that low dose, individualized GH
replacement therapy improves cardiac function with less
risk of developing cardiac hypertrophy. This may explain,
combined with the increased muscle strength, the improved
exercise capacity in GH-deficient adults observed after GH
replacement. However, if an inappropriately high dose of
GH is given, there is a risk of an unwanted increment in left
ventricular mass, particularly in elderly GH-deficient
patients during long-term treatment.
Cardiac structure in acromegaly
Acromegaly is usually a slowly progressing disease where
gradually signs of changes in cardiac structure and function
develop in a considerable number of patients. Advanced
acromegalic cardiomyopathy is characterized by cardio-
megaly, ventricular hypertrophy, replacement fibrosis, and
degeneration of cardiomyocytes [47, 75]. The precise
mechanism for this gradual decline in cardiac structure is
not known. However, transgenic mice overexpressing bGH
were also found to have deterioration in myocardial bio-
energetics that was linked to ultrastructural changes in
mitochondria and depression of systolic function [76].
Treatment strategies for acromegaly include surgery and
pharmacological options, mainly with long-acting
somatostatin analogs, a GH-antagonist and dopamine
agonists. In therapy resistant cases, radiotherapy may also
be an additional option. It has been reported that both
surgery and pharmacological treatments with a decrease in
GH and IGF-I levels lead to improvement in cardiac
structure and function (for review see [48].
GH/IGF-I and contractility
The notion of GH and IGF-I as molecules endowed with
stimulatory properties on myocardial contractility is inter-
esting but so far, only demonstrated in experimental stud-
ies. In line with reports on cardiac hypertrophy, there are
several in vitro studies demonstrating direct effects of IGF-
I on intrinsic cardiac contractility [77–79], while there is
still so far no evidence of direct, IGF-I-independent effects
of GH on cardiac contractility. However, if animals are
treated with GH in vivo, allowing stimulation of IGF-I
synthesis, subsequent in vitro assessment shows improved
contractility [80, 81]. Accordingly, decreased contractility
has been demonstrated in dwarf rats with GH/IGF-I defi-
ciency [82–84]. In contrast, a paradoxical enhancement of
cardiac contractility was observed in the IGF-I mutant
mouse [18].
At least three different mechanisms have been suggested
for the GH/IGF-I to induce increased cardiac contractility:
1. altered intracellular Ca2? transients, 2. increased sensi-
tivity of myofilaments to Ca2?, and 3. a shift in myosin
isoforms.
Regarding intracellular Ca-transients, IGF-I has been
shown to acutely affect Ca2? currents within the cardio-
myocyte, with increased peak Ca2? levels [78, 85] and an
altered time course of the current [78] in association with
increased contractility. Specifically, the activity of L-type
Ca2?-channels was acutely increased by IGF-I in vitro
[86]. In cardiomyocytes from acromegalic rats, the action
potential duration was increased due to a decrease in
density of a transient outward current carried by K?,
which, in turn prolongs the Ca2?-influx through L-type
Ca2?-channels [87]. In contrast to other in vitro studies, the
acute increase of inotropy by IGF-I was associated with
decreased peak Ca2? levels but increased Ca2? sensitivity
of the contractile elements in isolated whole heart prepa-
rations [79]. No influence of GH on Ca2? currents has been
seen in acute settings [79, 85], while after more long-term
treatment in vivo, GH has been suggested to increase peak
intracellular Ca2? levels measured ex vivo [80, 81].
Accordingly, reduced peak intracellular Ca2? levels as well
as slowed intracellular Ca2?-clearing have been demon-
strated in GH/IGF-I deficiency [84], while others report
28 Endocrine (2015) 48:25–35
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peak intracellular Ca2? levels to be unchanged in GH/IGF-
I deficiency [83].
To date, little has been known about possible gene
regulations involved in the action of GH/IGF-I in altering
Ca2? handling. An up-regulation of sarcoplasmic reticulum
ATPase (SERCA) levels has been suggested to contribute
to the increased contractile function elicited by GH after
myocardial infarction [81] and in rapid pacing heart failure
[88], while another study [89] has not been able to detect
any change in SERCA expression. SERCA may increase
contractility by enhancement of the so-called contractile
reserve, i.e., the Ca2? storage within the sarcoplasmic
reticulum, allowing higher peak Ca2? levels upon stimu-
lation. Ueyama et al. [90] also suggested that GH treatment
in cardiomyopathic, but not normal, hamsters preserved
cardiac ryanodine receptor density.
Myofilament Ca2?-sensitivity and myosin isoform shift.
GH/IGF-I has been suggested to increase myofilament
Ca2? sensitivity [79, 84, 91] and maximum Ca2? activated
force [79, 80, 91]. However, data are conflicting, and others
report unchanged [85] or even decreased [80] myofilament
Ca2? sensitivity by GH/IGF-I. In dwarf rats, unchanged
myofilament Ca2? sensitivity has been reported [83, 84],
although maximum Ca2? activated tension was less [83].
In animal models of GH excess, a shift toward a myosin
isoform with lower ATPase activity has been demon-
strated, which may decrease the energy demand of the
contractile process [91, 92].
Taken together, available data suggest that GH/IGF-I
may increase cardiac contractility through modulations of
intracellular Ca2? transients, myofilament Ca2? sensitivity,
and myosin isoform expression, although the findings
depend upon different experimental settings and among
studies. Besides regulation of ion channel activity, GH/
IGF-I may also regulate the expression of ion channels.
Solid evidence for increased contractility by GH and IGF-I
is still lacking.
Cardiovascular aspects of GHD
Cardiovascular risk factors
In addition to the cardiac dysfunction, several cardiovas-
cular risk factors are associated with adult GH deficiency.
These include insulin resistance [93, 94], unfavorable
alterations in serum lipid pattern including increased serum
low density lipoprotein (LDL)-cholesterol concentration
[95], decreased fibrinolysis [96], and increased sympathetic
nervous activity [3]. Other cardiovascular risk factors
beneficially affected by GH treatment include homocyste-
ine and C-reactive protein (for review see: [97]). In addi-
tion, pregnancy-associated plasma protein-A (PAPP-A) has
been found to be elevated in GHD patients [98]. This may
be of particular interest, since PAPP-A is both a cardio-
vascular risk factor and a mediator of IGF-I bioavailability
[98]. Body composition has a tendency to deteriorate in
hypopituitary adults with increased body fat and decreased
body cell mass [99]. Furthermore, extracellular water is
decreased, [32], which may result in reduced preload of the
heart (Starling effect). Finally, decreased sweating,
impaired thermoregulation, and increased risk for devel-
oping hyperthermia during exercise in hot environments
[100] have been observed in GH-deficient adult patients.
GH replacement therapy normalizes most of the car-
diovascular risk factors observed in hypopituitary patients
[101]. Body composition is rapidly normalized by GH
replacement therapy [95] and appears to be partly sustained
after 15 years of therapy [102]. Aberrations in serum lipid
concentrations and fibrinolysis are also improved by GH
replacement therapy [95, 103]. A modest improvement of
sympathetic nerve activity was found after 1 year of GH
replacement [31]. The effects by GH replacement on
insulin sensitivity are still controversial [104, 105],
although in one study, 7-year GH replacement provided
protection from the age-related decline in insulin sensi-
tivity [105].
Morbidity and mortality
A landmark retrospective study by Rose´n and Bengtsson
[32] showed doubled overall mortality due to increased
cardiovascular mortality in hypopituitary adults, as com-
pared with the normal population. The hypopituitary
patients in the study by Rose´n and Bengtsson [32] had
routine hormonal replacement therapy which did not
include GH at that time. Two additional retrospective
studies [106, 107], and one prospective study [108], have
confirmed that the increase in total mortality in hypopitu-
itary adults without GH replacement therapy is due to
increased cardiovascular mortality. A more recent study
was based on data recorded by the Board of Health and
Welfare in Sweden [109]. This study confirmed an
increased overall mortality in 1,411 hypopituitary patients
without GH replacement therapy [109]. The increase in the
total number of myocardial infarctions (fatal and non-fatal)
was less marked than the increase in cerebrovascular
events in this study [109]. The risk ratio for myocardial
infarction in the hypopituitary patients without GH
replacement therapy was 1.40, 95 % CI 1.10–1.75.
There is no abundance of data regarding the effect of
GH replacement therapy on cardiovascular morbidity and
mortality. In the report by Svensson et al. [109], there was,
however, also a prospective study of 289 hypopituitary
patients that received GH replacement therapy at a single
center. The mean duration of GH treatment was 60 months
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(range 2–118 months). It was demonstrated that the risk
ratio for myocardial infarctions was even lower in the 289
hypopituitary patients on GH replacement therapy than in
the general population. Taking into account that the rela-
tive risk of myocardial infarctions was increased in hypo-
pituitary patients without GH replacement, the reduced rate
of myocardial infarctions in hypopituitary on GH replace-
ment therapy clearly indicates that GH replacement therapy
will be effective in preventing myocardial infarctions in
hypopituitary adults. In a recent prospective observational
study on GH-deficient adults from the US on 1988 GH-
treated patients and 442 untreated and a mean follow-up for
2.3 years, there was no increase in overall mortality rate or
cardiovascular events between the two studied groups
[110]. However, the follow-up was comparatively short
which makes conclusion on long-term effects uncertain.
A potential therapeutic role for GH in heart failure?
Despite considerable advances in both medication strate-
gies and use of medical devices in patients with heart
failure in the last decades, the prognosis is still poor, and
there is a continued interest to develop alternative or
additional treatment modalities.
One of the first clinical publications to mention possible
beneficial effects of GH in heart failure was the paper by
Caidahl et al. [37] in 1994, describing improvement in
systolic function in GH-deficient patients treated with GH.
This triggered several research groups to study effects of
GH and/or IGF-I in experimental models with states of
impaired cardiac function. In an established rat model of
congestive heart failure following ligation of the left cor-
onary artery, GH and IGF-I have been found to increase
stroke volume and cardiac output [111, 112], also in the
presence of ACE inhibition [113]. GH treatment of rats
with experimental myocardial infarction has also been
found to improve myocardial bioenergetics [114] and long-
term survival [115].
The first clinical studies regarding GH treatment in heart
failure were limited to case reports [116, 117] where GH
administration dramatically improved cardiac function. A
subsequent small open study of seven patients with idio-
pathic dilated cardiomyopathy and CHF without GH defi-
ciency, who received GH treatment for 3 months,
demonstrated considerable improvement of left ventricular
ejection fraction, cardiac output, and exercise performance
[118]. Further studies have demonstrated beneficial effects
in patients with CHF due to both ischemic and idiopathic
dilated cardiomyopathy with improvements in hemody-
namics when GH was added both as a maintenance therapy
and as short-term infusion [119, 120]. Moreover, another
interesting observation was that patients with a low base-
line serum IGF-I had less beneficial effects of an acute GH
infusion [121]. A later study showed that GH treatment
decreased circulating levels of cytokines such as TNF-a
and IL-6 and apoptotic agents such as FAS and its soluble
ligand in patients with heart failure [122].
Even though a more recent placebo-controlled trial on
16 patients with CHF showed correction of endothelial
dysfunction and improved non-endothelium dependent
vasodilation [123], other randomized, placebo-controlled
studies have failed so far to show any significant GH-
mediated improvement of cardiac performance in patients
with heart failure, despite significant increases in IGF-I
[124, 125]. However, in a follow-up study of the same
patients in the former study, analyzed in more depth, Perrot
et al. [126], found a significant increase in left ventricular
mass, which correlated with serum IGF-I. Moreover, there
was a significant increase of ejection fraction in those
patients that responded with higher serum IGF-I levels
during GH treatment. Acevedo et al. [127] performed a
randomized controlled trial of 19 patients with daily GH
administration for 8 weeks. However, at the end of treat-
ment, there was no significant effect of GH on LVEF or
peak oxygen consumption, although left ventricular mass
was reported to be increased.
The prevalence of cardiac cachexia in patients with
chronic congestive heart failure has been uncertain. How-
ever, in a recent study, it was estimated to be 10.5 % in a
population of 238 patients with stable congestive heart
failure [128]. Importantly, cardiac cachexia in severe heart
failure could lead to a number of endocrine disturbances
[129], including acquired GH resistance and may explain
some of the diverse responses to GH therapy observed in
different patients [130].
The reasons for the lack of convincing positive effects of
GH on cardiac function in these randomized trials in all
likelihood depend upon several factors. Duration of treat-
ment has been relatively short (2–3 months) compared to
conventional heart failure trials, and the studies have so far
included only a small number of patients, which may also
contribute to lack of power and negative results. Encour-
agingly, a meta-analysis encompassing 12 clinical trials
still suggested that GH treatment had beneficial effects on
left ventricular geometry, ejection fraction, and exercise
parameters, all correlated to increase in serum IGF-I levels
[131]. Hence, whether GH treatment will finally find a
place in the treatment of heart failure remains to be
established and need to be studied in larger placebo-con-
trolled clinical trials.
A topic which has received increased attention during
the last years is the endocrine status of heart failure
patients. It has been suggested that multiple anabolic
deficiencies are common in heart failure patients and that
this may be associated with worse outcome [132–134]. At
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present, the literature is inconsistent regarding the GH/IGF-
I axis in heart failure describing both low levels of IGF-I
[133, 135, 136] and normal or even higher levels [137].
Possible explanations for these diverging results may be
due to heterogeneous heart failure patients and the use of
different IGF-I assays. Even less is known about GH
secretion in heart failure, although there are indications of
disturbed secretion [138]. A more recent study suggests
that as many as 40 % may fulfill criteria for GH deficiency
[139].
Recently, a novel approach in the selection of heart
failure patients to be treated with GH was taken by the
group of Sacca` and collaborators. Using a GH provocation
test, only patients that fulfilled criteria for GH deficiency
(n = 56) were enrolled in a randomized, single blind study
where they were treated with GH for 6 months. Here, GH
had a number of beneficial effects compared to controls,
including improved quality of life score, increased peak
oxygen uptake, exercise duration, and flow-mediated
vasodilation. Moreover, GH treatment leads to a moderate
but significant increase in left ventricular ejection fraction
and a reduction in circulating N-terminal pro-brain natri-
uretic peptide levels [139]. Future studies with more robust
RCT design are needed to verify the validity of this
approach of selecting heart failure patients for GH. How-
ever, preliminarily, results so far are very promising.
Summary and conclusions
It can be summarized that GH appears to have a number of
important effects, both on the heart and the vasculature.
Furthermore, an intact GH/IGF-I system with neither
deficiency nor excess appears to be optimal for a normal
cardiovascular function. Anabolic impairment in heart
failure, including possible GH deficiency, opens up inter-
esting perspectives for new treatment modalities with
hormones in addition to conventional heart failure in the
future.
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